

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1626GMS

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 4 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 5 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 6 SEP 27 STANDARDS will no longer be available on STN
NEWS 7 SEP 27 SWETSCAN will no longer be available on STN
NEWS 8 OCT 28 KOREAPAT now available on STN
NEWS 9 NOV 18 Current-awareness alerts, saved answer sets, and current
search transcripts to be affected by CERAB, COMPUAB, ELCOM,
and SOLIDSTATE reloads

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:33:54 ON 29 NOV 2004

=> FIL REGISTRY
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY 1.26	TOTAL SESSION 1.26
-----------------------------	--------------------------

FILE 'REGISTRY' ENTERED AT 13:37:20 ON 29 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8
 DICTIONARY FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10740245.str



chain nodes :

20 21 22 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

5-20 10-21 20-21 20-23 21-22

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-12 10-11 10-15 11-12 12-13
 13-16 14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 5-20 20-21 21-22

exact bonds :

10-11 10-15 10-21 12-13 13-16 20-23

normalized bonds :

6-7 6-11 7-8 8-9 9-12 11-12 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :


containing 1 : 6 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:CLASS 21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 13:37:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1


=> S L1 SSS FULL
FULL SEARCH INITIATED 13:37:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS
SEARCH TIME: 00.00.01

19 ANSWERS

L3 19 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10740245A.str



chain nodes :

20 21 22 23 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

3-25 5-20 10-21 20-21 20-23 21-22

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-12 10-11 10-15 11-12 12-13
13-16 14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 5-20 20-21 21-22

exact bonds :

3-25 10-11 10-15 10-21 12-13 13-16 20-23

normalized bonds :

6-7 6-11 7-8 8-9 9-12 11-12 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 1 : 6 :

Match level :


 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS

L4 STRUCTURE UPLOADED

=> D L4

L4 HAS NO ANSWERS

L4 STR

Novelty CF₃

Structure attributes must be viewed using STN Express query preparation.

=> S L4
 SAMPLE SEARCH INITIATED 13:39:33 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 1 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 1 TO 80
 PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L4

=> S L4 SSS FULL
 FULL SEARCH INITIATED 13:39:39 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 8 TO ITERATE


100.0% PROCESSED 8 ITERATIONS
 SEARCH TIME: 00.00.01

L6 8 SEA SSS FUL L4

=> D HIS

(FILE 'HOME' ENTERED AT 13:33:54 ON 29 NOV 2004)

FILE 'REGISTRY' ENTERED AT 13:37:20 ON 29 NOV 2004
 L1 STRUCTURE uploaded
 L2 3 S L1
 L3 19 S L1 SSS FULL
 L4 STRUCTURE uploaded
 L5 1 S L4
 L6 8 S L4 SSS FULL

 8 ANSWERS

10740245.trn

11/29/2004

=> **FIL CAPLUS**
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
311.68	312.94

FILE 'CAPLUS' ENTERED AT 13:39:51 ON 29 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2004 VOL 141 ISS 23
FILE LAST UPDATED: 28 Nov 2004 (20041128/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L3
L7
=> S L6
L8
=> d 17. ibib abs hitstr tot

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:550747 CAPLUS
DOCUMENT NUMBER: 141:89081
TITLE: Preparation of 9H-xanthene-9-carboxylic acid (oxazol-2-yl)amide derivatives as mGluR1 enhancers
INVENTOR(S): Hwylyer, Joerg; Kneflach, Frederic; Vieira, Eric; Wichmann, Juergen
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132792	A1	20040708	US 2003-740245	20031218
WO 2004056814	A1	20040708	WO 2003-EP14395	20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				

TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:


EP 2002-28747

A 20021223

OTHER SOURCE(S):

MARPAT 141:89081

GI



AB The title compds. (I; wherein one of R1 and R2 is CF₃, and the other is H; R3 and R3' are each independently H or halogen) or pharmaceutically acceptable salt thereof are prepared. These compds. are useful as mGluR1 enhancers in the treatment and prevention of neurol. disorders and diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's chorea, and dementia. Thus, to a solution of 150 mg (0.99 mmol, 1.0 equivalent) (4-trifluoromethoxyazol-2-yl)amine > and 6 mg (0.05 mmol, 0.05 equivalent) N,N-bis(methylamino)pyridine in 2 mL dry pyridine was added a solution of 245 mg (0.99 mmol) 9H-xanthene-carbonyl chloride in 2 mL CH₂Cl₂ dropwise at 0° and the mixture was stirred 1 h at 0° and then at room temperature overnight to give, after workup and recrystn. from EtOAc/hexane 250 mg (0.66 mmol, 66%) 9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide as white crystals.

IT 714971-87-6P, 9H-Xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714971-88-7P, 9H-Xanthene-9-carboxylic acid N-(5-trifluoromethoxyazol-2-yl)amide 714971-89-8P, 2-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714971-90-1P, 2-Fluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethoxyazol-2-yl)amide 714971-91-2P, 3-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714971-92-3P, 4-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714971-93-4P, 4-Fluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethoxyazol-2-yl)amide 714971-94-5P, 2,7-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714971-95-6P, 2,7-Difluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethoxyazol-2-yl)amide 714971-96-7P, 3,6-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714971-97-8P, 3,6-Difluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethoxyazol-2-yl)amide 714971-98-9P, 2-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714971-99-0P, 4-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethoxyazol-2-yl)amide 714972-04-0P,


3-Fluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethyloxazol-2-yl)amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 9H-xanthene-9-carboxylic acid (oxazol-2-yl)amide derivs. as mGlur1 enhancers for treatment and prevention of neurol. disorders and diseases)


RN 714971-87-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-88-7 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[5-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-89-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-90-1 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2-fluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-91-2 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-92-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-93-4 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-fluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-94-5 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2,7-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-95-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2,7-difluoro-N-[5-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-96-7 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3,6-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-97-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3,6-difluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)



RN 714971-98-9 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2-chloro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)



RN 714971-99-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-chloro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
 MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
 TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6462198

CA 2367368

EP 1171423

B1 20021008 US 2000-545622 20000410

AA 20001026 CA 2000-2367368 20000419

A1 20020116 EP 2000-929386 20000419

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

BR 2000009885

A 20020122 BR 2000-9885 20000419

TR 200103010

T2 20020521 TR 2001-200103010 20000419

JP 2002542229

T2 20021210 JP 2000-612262 20000419

NZ 514487

A 20040130 NZ 2000-514487 20000419

ZA 2001007837

A 20021223 ZA 2001-7837 20010921

NO 2001005064

A 20011018 NO 2001-5064 20011018

HR 2001000761

A1 20021231 HR 2001-761 20011019

US 2002091150

A1 20020711 US 2001-8827 20011210

US 6596743

B2 20030722

US 6803381

B1 20041012 US 2003-438361 20030514

EP 1999-107843 A 19990420

US 2000-545622 A3 20000410

WO 2000-EP3556 W 20000419

US 2001-8827 A3 20011210


PRIORITY APPLN. INFO.:

OTHER SOURCE(S):





MARPAT 133:321633

GI


Check Item




I




II



AB The title compd. I (R1 = H, lower alkyl; R2, R3 = independently H, alkyl, alkoxy, halo or CF₃; X = O, S or two hydrogen atoms not forming a bridge; A1, A2 = independently constitute benzo fusion or a fused 6-membered heterocycle containing 1 or 2 nitrogen atoms; B = R₄YC(:Z) {Y = O, S or bond; Z = O or S; R₄ = alkyl, alkenyl, alkynyl, benzyl, alkylpyridinyl, etc.}, or B = Q₁, Q₂, Q₃, Q₄ {R₅ and R₆ = H, alkyl, alkoxy, cyclohexyl,



RN 714972-04-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3-fluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:756670 CAPLUS

DOCUMENT NUMBER: 133:321633

TITLE: Preparation of carbamic acid derivatives and
evaluation of their use as metabotropic glutamate
receptor ligandsINVENTOR(S): Bleicher, Konrad; Mutel, Vincent; Vieira, Eric;
Wichmann, Jürgen; Woltering, Thomas *Wichmann*

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063166	A1	20001026	WO 2000-EP3556	20000419
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				

alkylcyclohexyl or CF₃ with at least one R₅ or R₆ = H}) and their pharmaceutically acceptable salts and methods of preparation are disclosed. Thus, II was obtained in 83% yield by reaction of 1-butanol with diphenylacetyl isocyanate. Compds. of the invention demonstrated both agonistic (IC₅₀ = 0.14-0.22 μ M) and antagonistic (IC₅₀ = 1.38-6.31 μ M) behavior toward group I mGlu receptors. As metabotropic glutamate receptor ligands, these compds. may be used in the control or prevention of acute and/or chronic neurol. disorders.


IT 302841-98-1P 302842-00-8P 302842-01-9P

302842-02-0P 302842-05-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of carbamic acid derivs. as metabotropic glutamate receptor ligands)


RN 302841-98-1 CAPPLUS

CN 9H-Xanthene-9-carboxamide, N-2-oxazolyl- (9CI) (CA INDEX NAME)




RN 302842-00-8 CAPPLUS

CN 9H-Xanthene-9-carboxamide, N-(5-ethyl-2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 302842-01-9 CAPPLUS

CN 9H-Xanthene-9-carboxamide, N-(5-methyl-2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 302842-02-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-(5-propyl-2-oxazolyl)- (9CI) (CA INDEX NAME)



RN 302842-05-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-(4-methyl-2-oxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 18 ibib abs hitstr tot

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:550747 CAPLUS
 DOCUMENT NUMBER: 141:89081
 TITLE: Preparation of 9H-xanthene-9-carboxylic acid
 (oxazol-2-yl)amide derivatives as mGluR1 enhancers
 INVENTOR(S): Huwyler, Joerg; Knoflach, Frederic; Vieira, Eric;
 Wiesmann, Juergen
 PATENT ASSIGNEE(S): Switz.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132792	A1	20040708	US 2003-740245	20031218
WO 2004056814	A1	20040708	WO 2003-EP14395	20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2002-28747	A 20021223
OTHER SOURCE(S): MARPAT 141:89081				
GI				



AB The title compds. (I; wherein one of R1 and R2 is CF₃, and the other is H; R³ and R^{3'} are each independently H or halogen) or pharmaceutically acceptable salt thereof are prepared. These compds. are useful as mGluR1 enhancers in the treatment and prevention of neurol. disorders and diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's chorea, and dementia. Thus, to a solution of 150 mg (0.99 mmol, 1.0 equivalent) (4-trifluoromethyloxazol-2-

yl)amine > and 6 mg (0.05 mmol, 0.05 equivalent) N,N-bis(methylamino)pyridine in 2 mL dry pyridine was added a solution of 245 mg (0.99 mmol) 9-xanthene-carbonyl chloride in 2 mL CH₂Cl₂ dropwise at 0° and the mixture was stirred 1^h at 0° and then at room temperature overnight to give, after workup and recrystn. from EtOAc/hexane 250 mg (0.66 mmol, 66%) 9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide as white crystals.


IT 714971-87-6P, 9H-Xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-89-8P, 2-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-91-2P, 3-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-92-3P, 4-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-94-5P, 2,7-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-96-7P, 3,6-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-98-9P, 2-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-99-0P, 4-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 9H-xanthene-9-carboxylic acid (oxazol-2-yl)amide derivs. as mGluR1 enhancers for treatment and prevention of neurol. disorders and diseases)


RN 714971-87-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-89-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-91-2 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-92-3 CAPLUS


CN 9H-Xanthene-9-carboxamide, 4-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-94-5 CAPLUS
CN 9H-Xanthene-9-carboxamide, 2,7-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 714971-96-7 CAPLUS
CN 9H-Xanthene-9-carboxamide, 3,6-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)



RN 714971-98-9 CAPLUS
CN 9H-Xanthene-9-carboxamide, 2-chloro-N-[4-(trifluoromethyl)-2-oxazolyl]-
(9CI) (CA INDEX NAME)



RN 714971-99-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-chloro-N- [4- (trifluoromethyl) -2-oxazolyl] -
(9CI) (CA INDEX NAME)

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

15.16 328.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL
ENTRY SESSION

CA SUBSCRIBER PRICE

-2.10 -2.10

STN INTERNATIONAL LOGOFF AT 13:40:58 ON 29 NOV 2004